- $12.45m
- -$302.20m
- $213.65m
U.S. STOCKS ON THE MOVE-Union Pacific, Micron, Uber
U.S. STOCKS ON THE MOVE-US airlines, Snowflake, Supermicro
Amarin gains on licensing deal with Italy's Recordati
Brief: Recordati Signs Exclusive Licensing & Supply Agreement With Amarin To Commercialize Vazkepa In Europe
Brief: Amarin Announces Exclusive License And Supply Agreement With Recordati
Amarin Corporation PLC reports results for the quarter ended March 31 - Earnings Summary
Amarin Corporation PLC expected to post a loss of 57 cents a share - Earnings Preview
Amarin Corporation PLC expected to post a loss of 57 cents a share - Earnings Preview
Brief: Amarin Confirms Effective Date For 1-For-20 ADS Ratio Change
Brief: Amarin Appoints Jec Capital Partners’ Michael Torok To Board Of Directors
Brief: Amarin Shareholders Radoff And Torok Says Amarin Should Immediately Run Strategic Review Maximizing Value For All Shareholders
Amarin Corporation PLC reports results for the quarter ended December 31 - Earnings Summary
Amarin Corporation PLC expected to post a loss of 5 cents a share - Earnings Preview
Brief: Amarin Corp - Nasdaq Granted 180 Days To Regain Nasdaq Compliance
Amarin Corporation PLC reports results for the quarter ended in September 30 - Earnings Summary
Amarin Corporation PLC expected to post a loss of 5 cents a share - Earnings Preview
Brief: Amarin Corp Says Tom Reilly To Resign As Executive Vice President And CFO Effective October 23, 2024
Drugmaker Apotex accuses Amarin of Vascepa monopoly in US lawsuit
U.S. STOCKS ON THE MOVE-Paramount Global, Core Scientific, Amarin